Derm-Biome Pharmaceuticals? topical therapy shows positive results?in?preclinical skin cancer trial: drug prevents?the development of?precancerous skin conditions?and?treats?existing skin?cancers?with no observable?side effects.?
April 18, 2024
VANCOUVER, British Columbia, April 17, 2024 (GLOBE NEWSWIRE) -- The rates of precancerous skin conditionsand skin cancersare soaring in many parts of the world.Actinic keratosis(AK)is the most commonform ofprecancer,withover40 millionAmericans a year developing thiscondition.Treating AKs before the cells become cancerous andspread to other parts of the bodyiscrucial.For those patients with multiple AKs,common treatment options are chemotherapy creams and photodynamic therapy.Although effective, these treatmentscome withsignificant side effects,suchasredness,blistering, and peeling,withrecovery timesthatcan belengthy anduncomfortable.The global actinic keratosis treatment market size is projected to reach as high as $10 billion USDby2031, fuelled by increasing cases of AK and rising healthcare spending.
Derm-BiomePharmaceuticals is a Vancouver-basedbiopharmaceutical company thathas developed atopicalanticancertreatmentforpatientswithorat high risk ofdevelopingmultipleAKs.In arecentUV-induced skin cancertrial,mice were exposed to UVB radiation over a period of 25 weeks. Theprolonged exposure mimics chronic sun exposure overtime andreplicates the gradual progression fromprecancerous skin conditionstocutaneous squamous cell carcinoma (cSCC).Topical application of Derm-Biomes compound prior to UVB exposure significantly reduced the number and size of precancer lesions,while treatment blockedthe progression ofsquamous cell carcinoma tumors.
FrdricCouture, Researcherand Head of PharmaceuticalSciencesat TransBIOtech:Myresearchgroupconductedthis studyusingDerm-Biomes compound. Thecompound exhibited a significant protective effect without toxicity or side effects.Moreover, existing tumor progression was blocked with drug treatment.We actually noticed animprovement tothe look of skintreated with thecompound.
Dr. Poul Sorensen, University of British Columbia Professor and Distinguished Scientist at BC Cancer Research Centre, and Derm-Biome CSO: The results of these studies are very promising. We tested our compound using a very aggressive UV-induced skin cancer model. We observed highly significant decreases in the number of tumors in treated miceandstrong preventative effects when mice werepretreated with the compound.These findings suggest that our compound has great potential to be a highly effective and well-tolerated agent for both the treatmentandprevention of squamous cell carcinoma.
Derm-Biome CEO Gordon Eberwein:Currently available topical treatments cause debilitating side effects that make them unattractive to patients.There is a real need for safer and more targeted topical therapies.
Derm-Biome expects to start topical formulation development this summer, with IND-enabling studies slated to begin in Q4.
About Derm-Biome Pharmaceuticals, Inc.
Derm-Biome Pharmaceuticals, Inc. is a preclinical biopharmaceutical company dedicated to improving skin health. We are developing novel topical therapies for inflammatory skin diseases and precancer/non-melanoma skin cancers that are both highly effective and well tolerated by skin.
Derm-Biomeisabout to kick offa $3M USDseedfundinground. For investor inquiries please contact:
Gordon Eberwein
geberwein@derm-biome.com
https://derm-biomepharmaceuticals.com
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/54b222f0-2c93-417d-8bba-33853a2dd94a
AAPR aggregates press releases and media statements from around the world to assist our news partners with identifying and creating timely and relevant news. All of the press releases published on this website are third-party content and AAP was not involved in the creation of it. Read the full terms.
